No Data
No Data
Ping An Securities: The terminal market resumes growth and selects varieties based on space and pattern
Ping An Securities released a research report saying that judging from changes in the scale and pattern of terminal drug use, the industry ushered in restorative growth in the post-pandemic era. Innovative drugs and varieties with high barriers and good patterns are growing faster than the overall growth rate.
Changes in Hong Kong stocks | Nuochengjianhua (09969) is now up more than 4%. ICP-488 completes phase II clinical trial for psoriasis, patients enrolled
The Zhitong Finance App learned that Nuocheng Jianhua (09969) is now up more than 4%. As of press release, it has risen 4.41% to HK$5.21, with a turnover of HK$11.394,400. According to the news, on May 16, Nuochengjianhua announced that the phase II clinical trial of the TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 developed independently by the company to treat psoriasis has completed patient enrollment. ICP-488 showed good efficacy and safety in a phase I study in treating patients with psoriasis. Furthermore, Goldman Sachs released a research report saying that Nuochengjianhua's sales were weak in the first quarter, and its obutinib sales were 1
Goldman Sachs: Target price raised to HK$8.6 for Nuochengjianhua's “buy” rating
Goldman Sachs released a research report stating that it gave Nuocheng Jianhua (09969) a “buy” rating, raised the company's sales forecast for the full year of this year from RMB 817 million to RMB 839 million, and lowered the profit estimates for each year from 2024 to 2026. The target price rose slightly from HK$8.58 to HK$8.6. According to the report, the company's sales were weak in the first quarter. Its sales of Orelabrutinib (Orelabrutinib) were 165 million yuan, up 9% year over year and down 13% from quarter to quarter. Recovery was slower than expected because new indications for treating relapsed/refractory marginal zone lymphoma (MZL) were included
InnoCare Pharma Concludes Subject Enrolment Phase II Psoriasis Trial
InnoCare Announces the Completion of Patient Enrollment in the Phase II Clinical Trial of ICP-488 for the Treatment of Psoriasis
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, today announced the completion of patient enrollment for the phase II clinical trial of ICP-488, a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor, for the treatment of psoriasis.
Innocare Pharma Posts Q1 Loss
Innocare Pharma (HKG:9969) posted a loss attributable to shareholders of 142.4 million yuan, or 0.08 yuan per share, for the first quarter, according to a Monday filing with the Hong Kong Exchange. Op
No Data